Gemtuzumab ozogamicin
| Klinički podaci | |
|---|---|
| Prodajno ime | Mylotarg, Mylotarg (Wyeth) |
| Drugs.com | ozogamicin.html Monografija |
| Način primene | Intravenozno |
| Identifikatori | |
| CAS broj | 220578-59-6  |
| ATC kod | L01XC05 (WHO) |
| DrugBank | DB00056 |
| ChEMBL | CHEMBL1201506 |
| Hemijski podaci | |
| Molarna masa | 0,000 |
| Fizički podaci | |
| Tačka topljenja | 61 °C (142 °F) |
Gemtuzumab ozogamicin (Mylotarg) je lek vezan za monoklonalno antitelo koji je korišten za tretiranje akutne mijelocitne leukemije tokom perioda 2000-2010. On je povučen sa tržišta u junu 2010, kad su klinička ispitivanja pokazala da povećava stopu smrtnosti pacijenata i da nema prednosti od njegove primene u odnosu na konvencionalne terapije kancera.[1][2][3][4][5]
Reference[уреди | уреди извор]
- ^ Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R: Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001 Jun;7(6):1490-6. PMID 11410481
- ^ Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH: Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001 Jul 15;92(2):406-13. PMID 11466696
- ^ Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Alyea EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ: Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003 Sep 1;102(5):1578-82. Epub 2003 May 8. PMID 12738663
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709
. PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
Literatura[уреди | уреди извор]
- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze[уреди | уреди извор]
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
